%0 Journal Article
%A Stahler, Arndt
%A Hoppe, Beeke
%A Na, Il-Kang
%A Keilholz, Luisa
%A Müller, Lothar
%A Karthaus, Meinolf
%A Fruehauf, Stefan
%A Graeven, Ullrich
%A Fischer von Weikersthal, Ludwig
%A Goekkurt, Eray
%A Kasper, Stefan
%A Kind, Andreas Jay
%A Kurreck, Annika
%A Alig, Annabel Helga Sophie
%A Held, Swantje
%A Reinacher-Schick, Anke
%A Heinemann, Volker
%A Horst, David
%A Jarosch, Armin
%A Stintzing, Sebastian
%A Trarbach, Tanja
%A Modest, Dominik Paul
%T Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
%J Journal of clinical oncology
%V 41
%N 16
%@ 0732-183X
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2023-00706
%P 2975-2987
%D 2023
%Z 2023 Jun 1;41(16):2975-2987
%X Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) after Pmab + mFOLFOX6 induction within the randomized phase II PanaMa trial.CMSs were determined in the safety set (ie, patients that received induction) and full analysis set (FAS; ie, randomly assigned patients who received maintenance) and correlated with median progression-free survival (PFS) and overall survival (OS) since the start of induction or maintenance treatment and objective response rates (ORRs). Hazard ratios (HRs) and 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37018649
%R 10.1200/JCO.22.02582
%U https://inrepo02.dkfz.de/record/275259